Phase II NaV 1.7 Pain Study Success... :)

Convergence Pharmaceuticals announced an extremely successful Phase II study result for its NaV 1.7 sodium channel blocker.

Their minimum definition of success was 30% of patients showing improvement and the study confirmed that 70% of patients showed improvement for treatment of trigeminal neuralgia (severe facial pain):

This is very good news...

Thank you Don. I have had Major Chronic Pain since 2001 and am always in search of new pain mgmt options and new treatments on the horizon. I really do appreciate your post !!

Tracy Z.